WO2000059886A3 - Benzimidazole abd imidazolophyridine derivaties, their preparation and their use as selective modulators of bradykinin b2 (=bk-2) receptors - Google Patents

Benzimidazole abd imidazolophyridine derivaties, their preparation and their use as selective modulators of bradykinin b2 (=bk-2) receptors Download PDF

Info

Publication number
WO2000059886A3
WO2000059886A3 PCT/US2000/008568 US0008568W WO0059886A3 WO 2000059886 A3 WO2000059886 A3 WO 2000059886A3 US 0008568 W US0008568 W US 0008568W WO 0059886 A3 WO0059886 A3 WO 0059886A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkylamino
mono
bradykinin
receptors
Prior art date
Application number
PCT/US2000/008568
Other languages
French (fr)
Other versions
WO2000059886A2 (en
Inventor
Robert W Desimone
Alan Hutchison
Kenneth Shaw
George D Maynard
John M Peterson
Richard Lew
Harry L Brielmann
Original Assignee
Neurogen Corp
Robert W Desimone
Alan Hutchison
Kenneth Shaw
George D Maynard
John M Peterson
Richard Lew
Harry L Brielmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp, Robert W Desimone, Alan Hutchison, Kenneth Shaw, George D Maynard, John M Peterson, Richard Lew, Harry L Brielmann filed Critical Neurogen Corp
Priority to CA002369544A priority Critical patent/CA2369544A1/en
Priority to JP2000609398A priority patent/JP2002541145A/en
Priority to EP00919946A priority patent/EP1165518A2/en
Priority to AU40553/00A priority patent/AU4055300A/en
Publication of WO2000059886A2 publication Critical patent/WO2000059886A2/en
Publication of WO2000059886A3 publication Critical patent/WO2000059886A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed are compounds of formula (I) or pharmaceutically acceptable salts thereof wherein: R1 is not 3-fluorobenzyl and represents (C2-C6) alkenyl, aryl (C1-C6)alkyl or heteroaryl (C1-C6)alkyl, OR7, O(CH2)nC(O)R7, O(CH2)nNR7R8, O(CH2)nCO2R7, NR7COR8, COR7, CONR7R8 or CO2R7; R2 represents hydrogen, hydroxy, halogen, trifluoromethyl, trifluoromethoxy, amino (C1-C6)alkyl, mono- or di(C1-C6)alkylamino (C1-C6), or mono- or di(C1-C6)alkylamino(C1-C6)alkoxy; or OR7, O(CH2)nC(O)R7, O(CH2)nNR7R8, O(CH2)nCO2R7, NR7COR8, COR7, CONR7R8 or CO2R7; R3 represents (C1-C6)alkyl; R4 represents halogen or trifluoromethyl; R5 and R6 represent hydrogen, trifluoromethyl, triluoromethoxy, cyano, (C1-C6)alkyl, halogen, (C1-C6)alkylamino(C1-C6)alkyl, mono or di(C1-C6)alkylamino(C1-C6), or mono- or di(C1-C6)alkylamino(C1-C6)alkoxy; or together form a 5 or 6 membered aromatic ring which is optionally substituted. X represents a bond or CH2 which is optionally mono- or disubstituted with a (C1-C6)alkyl or (C1-C6)alkoxy; and A, B, C and D are the same or different and represent CRp or N with the proviso that not more than two of A,B, C and D represent N; which compounds are selective modulators of Bradykinin B2 receptors.
PCT/US2000/008568 1999-04-02 2000-03-31 Benzimidazole abd imidazolophyridine derivaties, their preparation and their use as selective modulators of bradykinin b2 (=bk-2) receptors WO2000059886A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002369544A CA2369544A1 (en) 1999-04-02 2000-03-31 Aryl and heteroaryl fused aminoalkyl-imidazole derivatives:selective modulators of bradykinin b2 receptors
JP2000609398A JP2002541145A (en) 1999-04-02 2000-03-31 Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: Bradykinin B2 receptor selective modulators
EP00919946A EP1165518A2 (en) 1999-04-02 2000-03-31 Benzimidazole and imidazolopyridine derivatives, their preparation and their use as selective modulators of bradykinin b2 (= bk-2) receptors
AU40553/00A AU4055300A (en) 1999-04-02 2000-03-31 Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of Bradykinin B2 receptors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12750599P 1999-04-02 1999-04-02
US28532799A 1999-04-02 1999-04-02
US60/127,505 1999-04-02
US09/285,327 1999-04-02

Publications (2)

Publication Number Publication Date
WO2000059886A2 WO2000059886A2 (en) 2000-10-12
WO2000059886A3 true WO2000059886A3 (en) 2001-09-13

Family

ID=26825697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008568 WO2000059886A2 (en) 1999-04-02 2000-03-31 Benzimidazole abd imidazolophyridine derivaties, their preparation and their use as selective modulators of bradykinin b2 (=bk-2) receptors

Country Status (5)

Country Link
EP (1) EP1165518A2 (en)
JP (1) JP2002541145A (en)
AU (1) AU4055300A (en)
CA (1) CA2369544A1 (en)
WO (1) WO2000059886A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509366B2 (en) 2000-01-18 2003-01-21 Neurogen Corporation Substituted imidazoles as selective modulators of Bradykinin B2 receptors
KR20030060904A (en) * 2000-10-06 2003-07-16 뉴로젠 코포레이션 Benzimidazole and indole derivatives as CRF receptor modulators
PA8535601A1 (en) 2000-12-21 2002-11-28 Pfizer BENZIMIDAZOL AND PIRIDILIMIDAZOL DERIVATIVES AS LIGANDOS FOR GABAA
US6903126B2 (en) 2001-07-09 2005-06-07 Schering Ag 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
DE10135050A1 (en) * 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- or O-substituted benzimidazole derivatives, their use for the preparation of medicaments and pharmaceutical preparations containing them
CA2472470A1 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
CN1902181A (en) 2003-10-28 2007-01-24 沃泰克斯药物股份有限公司 Benzimidazoles useful as modulators of ion channels
TW201031665A (en) 2009-02-04 2010-09-01 Gruenenthal Gmbh Substituted indole-compound
AR118983A1 (en) * 2019-05-23 2021-11-17 Pharvaris Gmbh CYCLIC BRADYKININ RECEPTOR ANTAGONISTS

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000730A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997011069A1 (en) * 1995-09-18 1997-03-27 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic compounds as bradykinin antagonists
WO2000059905A1 (en) * 1999-04-02 2000-10-12 Neurogen Corporation ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS
WO2000059887A1 (en) * 1999-04-02 2000-10-12 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000730A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997011069A1 (en) * 1995-09-18 1997-03-27 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic compounds as bradykinin antagonists
WO2000059905A1 (en) * 1999-04-02 2000-10-12 Neurogen Corporation ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS
WO2000059887A1 (en) * 1999-04-02 2000-10-12 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AHLUWALIA A. & PERRETTI M.: "B1 receptors as a new inflammatory target. Could this B the 1?", TRENDS IN PHARMACOLOGICAL SCIENCES, GB, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, vol. 20, no. 3, March 1999 (1999-03-01), pages 100 - 104, XP004162861, ISSN: 0165-6147 *

Also Published As

Publication number Publication date
WO2000059886A2 (en) 2000-10-12
JP2002541145A (en) 2002-12-03
EP1165518A2 (en) 2002-01-02
CA2369544A1 (en) 2000-10-12
AU4055300A (en) 2000-10-23

Similar Documents

Publication Publication Date Title
ES2185338T3 (en) DERIVATIVES OF FUMAGILOL AND PROCEDURES FOR ITS MANUFACTURE.
NZ518542A (en) Triphenylalkene derivatives and their use as selective estrogen receptor modulators
MX9700883A (en) Substituted quinazoline derivatives.
TW347387B (en) Piperidine derivatives
WO2002044153A8 (en) 4-6-diphenyl pyridine derivatives as antiinflammatory agents
MY114679A (en) Aroyl-piperidine derivatives
BG106116A (en) 5-cyano-2-aminopyrimidine derivatives
ZA9811576B (en) Anilide derivative, production and use thereof.
MXPA02009706A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts.
WO2001062705A8 (en) Aminoalcohol derivatives
WO2000059886A3 (en) Benzimidazole abd imidazolophyridine derivaties, their preparation and their use as selective modulators of bradykinin b2 (=bk-2) receptors
YU94103A (en) Novel sulfonic acid derivatives
MY138826A (en) 2,7-substituted indoles
YU21100A (en) Isoquinolines as urokinase inhibitors
NO964698D0 (en) Bicyclic amine derivatives as inhibitors of nitric oxide synthetase
DE60005689D1 (en) NEW AMINOBENZOPHENONE
ES2191341T3 (en) DERIVATIVES OF 2-PHENOXIANILINE.
BR0213731A (en) Silicon Compounds
CO5160261A1 (en) SUBSTITUTED BIFENYL DERIVATIVES THAT ARE NK-1 ANTAGONISTS, THEIR SYNTHESIS PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
TW429253B (en) Novel pyrazole compounds
NO961404L (en) 4 indolylpiperazinyl derivatives
EP1434762A4 (en) 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor
PL341281A1 (en) Novel acronicin compounds, method of obtaining them and pharmacological compoistions containing such compounds
ATE289992T1 (en) PROTECTED TYROSINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR THE PRODUCTION OF O-(2-?18 F)-FLUORETHYL)-L-TYROSINE
BG104037A (en) 6-pyrrolidin-2-ylpyrindine derivatives, their preparation and application in therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2369544

Country of ref document: CA

Ref country code: JP

Ref document number: 2000 609398

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2369544

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000919946

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000919946

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000919946

Country of ref document: EP